SPEAKERS FROM ALL OVER THE WORLD

 

190   speakers are confirmed as of March 22nd. Here are some of the names that will be joining us:

Christopher Adams, Chief Executive Officer, Andarix Pharmaceuticals

Christopher Adams at World Orphan Drug Congress USA 2017

Chris Adams, CEO, Andarix Pharmaceuticals

Chris Adams at World Orphan Drug Congress USA 2017

Sudhir Agrawal, President of Research, Idera Pharmaceuticals, Inc.

Steven Anderson, Chief Scientific Officer, Covance

Einar Andreassen, Senior Adviser, Norwegian Medicines Agency

Irene Aquino, Senior Director, Patient Advocacy and Engagement, Alnylam Pharmaceuticals

Irene Aquino at World Orphan Drug Congress USA 2017

Diego Ardigo, Project Leader for Advanced Therapies, CHIESI Farmaceutici Spa

Diego Ardigo at World Orphan Drug Congress USA 2017

Donna Armentano, Global Head of Gene Therapy, Pfizer

Heather Ascani, Business Operations, Applied Systems Biology Core Internal Medicine – Nephrology, University of Michigan

Heather Ascani at World Orphan Drug Congress USA 2017

Alison Bateman House, Assistant Professor, Division of Medical Ethics, New York University Langone Medical Center

Michelle Berg, Vice President, Patient Advocacy, Abeona Therapeutics Inc.

Diana Bharucha, Assistant Professor of Neurology, Children’s National Health System

Diana Bharucha at World Orphan Drug Congress USA 2017

Sonal Bhatia, Vice President, North America Medical Lead, Pfizer Rare Disease

Stella Blackburn, VP, Global Head of Risk Management, QuintilesIMS

Stella Blackburn at World Orphan Drug Congress USA 2017

Dale Bodian, Manager Bioinformatics Scientist, Inova Translational Medicine Institute

Nadia Bodkin, Founder, EDSers United & Community Engagement Team Leader, rareLife solutions

John Boland, VP pro dev, Atlantic Research Group Inc

John Boland at World Orphan Drug Congress USA 2017

Jill Bonjean, Corporate and Foundation Relations Director, EURORDIS

Jill Bonjean at World Orphan Drug Congress USA 2017

Katrine Bosley, Chief Executive Officer, Editas Medicine

Katherine Brandt, Manager, Marketing and Sales Operations, Afton Scientific Llc

Katherine Brandt at World Orphan Drug Congress USA 2017

Ari Brettman, Principal, Clarus Ventures

Ari Brettman at World Orphan Drug Congress USA 2017

Murray Brilliant, Senior Research Scientist and Center Director, Marshfield Clinic Research Foundation

Max Bronstein, Chief Advocacy & Science Policy Officer, EveryLife Foundation for Rare Diseases

Philip J. Brooks, Program Director, Office of Rare Diseases Research, NCATS, NIH

Philip J. Brooks at World Orphan Drug Congress USA 2017

Anna Bucsics, External Lecturer, MoCA board member, University of Vienna

Anna Bucsics at World Orphan Drug Congress USA 2017

Shawn Burgess, Senior Investigator, Translational and Functional Genomics Branch, Head, Developmental Genomics Sect, NHGRI, NIH

Molly Burich, Associate Director of Public Policy, Biosimilars, Pipeline and Reimbursement, Boehringer Ingelheim

Andrea Califano, Chair, Systems Biology Department, Columbia University U.S.A.

Carlos Camozzi, Group Chief Medical Officer, Simbec-Orion

Jeff Ceitlin, Chief Commercial Officer, HVH Patient Precision Analytics

Fabrice Chartier, Chief Operating Officer, Simbec-Orion

Angela Chaves, President, Federacion Colombiana de Enfermedades Raras

William W. Chin, CMO, Executive VP, Science and Regulatory Affairs, PhRMA

Leah Christl, AD,Therapeutic Biologics & Biosimilars, F.D.A.

Leah Christl at World Orphan Drug Congress USA 2017

Margaret Collins, Professor of Pediatrics, Cincinnati Childrens Hospital

Francesca Cook, Director, Pricing and Market Access, RegenxBio

Francesca Cook at World Orphan Drug Congress USA 2017

Jodi Cook, Chief Operating Officer, Agilis Biotherapeutics

John Coster, Director, Division of Pharmacy, Center for Medicare and Medicaid Services

John F. Crowley, Chairman and Chief Executive Officer, Amicus Therapeutics

John F. Crowley at World Orphan Drug Congress USA 2017

Gregory Daniel, Deputy Director, Duke University

Rajiv Datar, Co Founder and Chief Executive Officer, D.N.X. Biopharmaceuticals Inc

Rajiv Datar at World Orphan Drug Congress USA 2017

Jefferson Davis, Chief Business Officer, Acer Therapeutics

Jefferson Davis at World Orphan Drug Congress USA 2017

Ronald DeBellis, Chief Scientific Officer, National Organization for Rare Disorders

Ronald DeBellis at World Orphan Drug Congress USA 2017

Peter Dehnel, Medical Director, Blue Cross and Blue Shield of Minnesota

Peter Dehnel at World Orphan Drug Congress USA 2017

Keith DeMatteo, Director, Global Procurement, Bristol Myers Squibb

Daniel Donovan, Co-Founder and CEO, rareLife solutions

Kelly Du Plessis, Chief Executive Officer, Rare Diseases South Africa

Paul Eccles, PhD, Client Services Director, Cello Health Insight

Glyn Edwards, Chief Executive Officer, Summit Therapeutics

Florian Eichler, Associate Professor of Neurology, Massachusetts General Hospital

David Elvira Martinez, Director, CatSalut, Catalunya Health Service

Neal Farber, Chief Executive Officer, NeuroHealing Pharmaceuticals

Neal Farber at World Orphan Drug Congress USA 2017

Wildon Farwell, Senior Medical Director, Clinical Development, Biogen

Wildon Farwell at World Orphan Drug Congress USA 2017

Brian Flatley, Business Development Director, S3 Connected Health

Mary Frances Harmon, Head of Global Patient Advocacy, PTC Therapeutics

Pat Furlong, Founding President and Chief Executive Officer, Parent Project Muscular Dystrophy

William Gahl, Clinical Director, Director of the N.I.H. Undiagnosed Diseases Program

Vignesh Ganapathy, AD of Advocacy & Government Relations, EveryLife Foundation for Rare Diseases

Vignesh Ganapathy at World Orphan Drug Congress USA 2017

Chris Garabedian, Chairman, Xontogeny LLC

Eric Gascho, Vice President of Government Affairs, National Health Council

Pamela Gavin, Chief Operating Officer, National Organization for Rare Disorders

Jayne Gershkowitz, Chief Patient Advocate, Amicus Therapeutics Inc

Dr Christopher Gibson, Chief Executive Officer, Recursion Pharmaceuticals

Michael Goettler, Global President, Pfizer Rare Disease

Jonathan Goldsmith, Associate Director Rare Diseases Program, Food And Drug Administration

Jonathan Goldsmith at World Orphan Drug Congress USA 2017

Rashmi Gopal-Srivastava, Dir, Extramural Research Program, Office Rare Diseases, National Institutes of Health

Hazel Gorham, Senior Director of Biosimilars Development, PRA Health Sciences

Hazel Gorham at World Orphan Drug Congress USA 2017

Scott Gray, Chief Executive Officer, Clincierge

James Greenwood, Chief Executive Officer, Biotechnology Industry Organization

Stephen Groft, Senior Advisor to the Director, NCATS, N.I.H

Yi Han, Executive Vice President of Market Access and HEOR, Cello Health Market Access

Colin Hayward, Chief Medical Officer, Premier Research

Gudrun Helga Haroardottir, Director, Einstok Born Support Group For Children With Rare Disorders

Gudrun Helga Haroardottir at World Orphan Drug Congress USA 2017

Johan Heylen, Chief Commercial Officer, Ablynx

Kenneth Hobby, President, Cure SMA

Angus Hogg, Vice President Hunters (MPSII) Franchise, Shire Pharmaceuticals Ltd

Angus Hogg at World Orphan Drug Congress USA 2017

Kay holcombe, Senior Vice President for Science Policy, Biotechnology Industry Organization (BIO)

Kay holcombe at World Orphan Drug Congress USA 2017

Tony Howell, Co-Founder & COO, rareLife solutions

Kate Hudson Farmer, Director, Front-End Innovation, Drug Delivery, Medicom Innovation Partner a/s

Kate Hudson Farmer at World Orphan Drug Congress USA 2017

Wills Hughes-Wilson, Senior Vice President, Chief Patient Access Officer, Sobi

Michelle Hylan, CEO, Innov8tive Research Consulting, Consultant, Innov8tive Research Consulting

Michelle Hylan at World Orphan Drug Congress USA 2017

Reina Improgo, Senior Research Scientist, Idera Pharmaceuticals, Inc.

Reina Improgo at World Orphan Drug Congress USA 2017

Raul Insa, Founder and Chief Executive Officer, SOM Biotech SL

Raul Insa at World Orphan Drug Congress USA 2017

Dr Cynthia Jackson, VP & Head, Pediatric & Rare Disease Cnrts of Excellence, QuintilesIMS

Dr Cynthia Jackson at World Orphan Drug Congress USA 2017

Edmund Jessop, Medical Adviser, National Health Service

Mehul Jhaveri, Director, Medical Value Based Outcomes, Biogen

Mehul Jhaveri at World Orphan Drug Congress USA 2017

Ashley Kamil, Vice President, Digital Services, ClinicalMind

Matt Kapusta, Chief Executive Officer, uniQure

Matt Kapusta at World Orphan Drug Congress USA 2017

Derek Kelaita, VP, Business Development, ArmaGen Technologies

Jas Khera, Managing Director EU, WEP Clinical

Jas Khera at World Orphan Drug Congress USA 2017

Sven Kili, Vice President and Head of Gene Therapy Development, GlaxoSmithKline

Takashi K Kishimoto, Chief Scientific Officer, Selecta Biosciences Inc

Diane Kleinermans, Advisor to the Ministry of Health and Social Affairs Belgium, Belgian Federal Government

Ragnar Klingberg, CEO, EmeraMed

Christopher Komelasky, Senior Director, Site and Patient Access, PPD

Walter Kowtoniuk, Director, Strategy and Operations, Fulcrum Therapeutics

Matthias Kretzler, Professor of Internal Medicine, Computational Medicine and Bioinformatics, University of Michigan

Karen Krumeich, Senior Vice President & Chief Financial Officer, Soligenix

Karen Krumeich at World Orphan Drug Congress USA 2017

Niels Kure, Director, Front-End Innovation, Drug Delivery, Medicom Innovation Partner a/s

Niels Kure at World Orphan Drug Congress USA 2017

Jennifer Kwon, Associate Professor of Neurology and Pediatrics, University of Rochester

David Lapidus, President, Lapidus Data

David Lapidus at World Orphan Drug Congress USA 2017

David Larwood, CEO and Founder, Valley Fever Solutions

Yann Le Cam, Chief Executive Officer, EURORDIS

Nadea Leavitt, Engagement Mgr, Predictive Analytics, RW Insights, QuintilesIMS

Nadea Leavitt at World Orphan Drug Congress USA 2017

John Leonard, Executive Vice President, R&D, Intellia Therapeutics Inc

Nick Leschly, President and Chief Executive Officer, bluebird bio

Aneta Lipińska, Head of Analysis and Strategy Division, President's Office, Agency for Health Technology Assessment and Tariff System

Aneta Lipińska at World Orphan Drug Congress USA 2017

David Litwack, Personalized Medicine Staff, U.S. Food And Drug Administration

Aoife M Brennan, Chief Medical Officer, Synlogic Therapeutics

Jack M. Mycka, Chief Executive Officer, Medical Marketing Economics

Jack M. Mycka at World Orphan Drug Congress USA 2017

Alastair Macdonald, Exec Director, RWLP Strategy, Global, INC Research

Alastair Macdonald at World Orphan Drug Congress USA 2017

Stephen Marcus, Chief Executive Officer, Cantex Pharmaceuticals

Jeffrey D. Marrazzo, Co Founder and Chief Executive Officer, Spark Therapeutics

Marc Martinell, Chief Executive Officer, Minoryx Therapeutics

John Maslowski, CEO, Fibrocell

Gary Mathias, Chief Executive Officer, Thetis Pharmaceuticals Llc

Gary Mathias at World Orphan Drug Congress USA 2017

Howard Mayer, SVP & Head of Global Clinical Development, Shire Pharmaceuticals

James McDermott, Vice President, Cello Health BioConsulting

John McKew, Chief Scientific Officer, Lumos Pharma

Paul Melmeyer, Associate Director of Public Policy, National Organization for Rare Disorders

Paul Melmeyer at World Orphan Drug Congress USA 2017

Jerry R. Mendell, Director, Center for Gene Therapy, Nationwide Children's Hospital

Debra Miller, CEO, CureDuchenne

Christopher Missling, President and Chief Executive Officer, Anavex Life Sciences

Juliet Moritz, Executive Director, Strategic Development, Rare Diseases, Premier Research

Richard Moscicki, Deputy Director for Science Operations, CDER, FDA

Joseph Musumeci, Senior Advisor, BluePrint Orphan

Jeff Myers, CEO, Medicaid Health Plans of America

Francois Nader, Former President & CEO, NPS, Board Chairman, Acceleron Pharma

Nikhil Nair, Assist Professor, Dept of Chemical and Biological Engineering, Tufts University

Yukiko Nishimura, President, NPO, Japan Patients Association, ASrid

David Norris, Rare Disease Patient Affairs Team Leader, Pfizer

Sean O'Bryan, Vice President, Regulatory Affairs & Quality Assurance, Lysogene

Sean O'Bryan at World Orphan Drug Congress USA 2017

Letitia O'Dwyer, Chief Executive Officer, New Zealand Organisation For Rare Disorders

Romina Ortiz, VP Policy & Patient Advocacy, Rare Genomics Institute

Luca Pani, Former Gen Director AIFA, CHMP and SAWP Member, European Medicines Agency

Anne Pariser, Deputy Director, Office of Rare Diseases Research, NCATS, NIH

Detlev Parow, Head of Department of Medicines, Therapeutic Appliances and Remedies, D.A.K.

Nancy Parsons, VP Commercial Operations, Pharma Products, Leadiant Biosciences

Nancy Parsons at World Orphan Drug Congress USA 2017

Douglas Paul, Vice President and Partner, Medical Marketing Economics

Douglas Paul at World Orphan Drug Congress USA 2017

Eric Pauwels, SVP & General Manager, Americas, PTC Therapeutics

Edmund Pezalla, Fomer VP Pharmaceutical Policy and Strategy, Aetna

Andreas Pleil, Sr Dr, Team Lead, Outcomes & Evidence Hematology, Pfizer

Horacio Plotkin, VP, Global Therapeutic Head, Pediatrics & Rare Diseases, PPD

Sy Pretorius, SVP and Chief Scientific Officer, PAREXEL International

Harsha Rajasimha, Co Founder, Organization for Rare Diseases India

Gayatri Rao JD., MD,, Director, Orphan Products Development, FDA

Kate Rawson, Contributing Editor, Prevision Policy

Kate Rawson at World Orphan Drug Congress USA 2017

Francis Reed, Director, The Children’s Fund for Glycogen Storage Disease Research

Adam Resnick, Director, Ctr for Data Driven Discovery in Biomedicine, The Children's Hospital of Philadelphia

Trevor Richter, Director, Common Drug Review and Optimal Use, CADTH

Kerry Robinson, Business Development Director Americas, S3 Connected Health

Philip Ross, Managing Director, J.P. Morgan Healthcare Investment Banking

Philip Ross at World Orphan Drug Congress USA 2017

Mark Rothera, Chief Commercial Officer, PTC Therapeutics

Mark Rothera at World Orphan Drug Congress USA 2017

Leonide Saad, CEO, Alkeus Pharmaceuticals Inc

Peter Saltonstall, CEO, National Organization For Rare Disorders

Amber Salzman, President and Chief Executive Officer, Adverum Biotechnologies

Amanda Samanek, Executive Director, Genetic and Rare Disease Network, Australia

Amanda Samanek at World Orphan Drug Congress USA 2017

Jillian Savarese, Group Account Supervisor, ClinicalMind

Scott Schliebner, Vice President, Scientific Affairs, Rare Diseases, PRA Health Sciences

Prof Matthias Schönermark, Chief Executive Officer, SKC Beratungsgesellschaft

Ana Maria Serrato Navas, Country Manager, Colombia, Aegerion Pharmaceuticals

Ana Maria Serrato Navas at World Orphan Drug Congress USA 2017

Samuel Seward, Site Chair, Department of Medicine, Mount Sinai Hospital

Samuel Seward at World Orphan Drug Congress USA 2017

Jim Shaffer, Chief Business Officer, Eiger Biopharmaceuticals

Jim Shaffer at World Orphan Drug Congress USA 2017

Alex Sherman, Director of Strategic Development and Systems, Massachusetts General Hospital Neurological Clinical Research Institute

Amandip Sidhu, EAP Director, WEP Clinical

Amandip Sidhu at World Orphan Drug Congress USA 2017

Ross Silver, Principal, Sylva International

Ross Silver at World Orphan Drug Congress USA 2017

Sascha Sonnenberg, Dipl.-Oec., MBA, Vice President Global CTD Sales & Operations, Marken

Sascha Sonnenberg at World Orphan Drug Congress USA 2017

Mark Sorrentino, Vice President, Scientific Affairs - Pediatrics, PRA Health Sciences

Mark Sorrentino at World Orphan Drug Congress USA 2017

Barbara Sosnowski, VP of External R&D Innovation and Head of Cambridge Research Units, Pfizer

Kaye Spratt, VP, Regulatory, Abeona Therapeutics LLC

Kaye Spratt at World Orphan Drug Congress USA 2017

Jeremy Springhorn, Partner Corporate Development, Flagship Ventures

Stephen Squinto, Venture Partner, Orbimed

Makoto Suematsu, Founding President, Japan Agency for Medical Research and Development

Makoto Suematsu at World Orphan Drug Congress USA 2017

Mary Szela, Chief Executive Officer, Novelion Therapeutics

Keren Tenenbaum, Assistant General Counsel, Patient Health and Impact, Pfizer

Adeline Vanderver, Pediatric Neurologist, Children's Hospital of Philadelphia

Adeline Vanderver at World Orphan Drug Congress USA 2017

Katie Verb, Director, Policy & Government Relations, Hemophilia Federation of America

Birgitte Volck, Senior Vice President, Head of R&D Rare Diseases, GlaxoSmithKline

Timothy Walbert, Chairman, President, and Chief Executive Officer, Horizon Pharma plc

Julie Walters, Founder, Raremark

Susan Ward, Founder and Executive Director, The Collaborative Trajectory Analysis Project (cTAP)

Ilyas Washington, , Alkeus Pharmaceuticals Inc

Ilyas Washington at World Orphan Drug Congress USA 2017

Leslie Wetherell, Exec Director, Rare Disease, Worldwide Clinical Trials

Leslie Wetherell at World Orphan Drug Congress USA 2017

Diane White, Assoc. Dir Development Sciences, Biomarin

Diane White at World Orphan Drug Congress USA 2017

James Wilson, Director, Orphan Disease Center, University of Pennsylvania

Barbara Wuebbels, Vice President of Patient Advocacy, Audentes Therapeutics

Michael Wyand, Former President and Chief Operating Officer, EPIRUS Biopharma

Michael Wyand at World Orphan Drug Congress USA 2017

Nora Yang, Director, Portfolio Management and Program Operations, NCATS, National Institutes of Health

Nora Yang at World Orphan Drug Congress USA 2017

Chen Yu, Managing Partner, Vivo Capital

 

DOWNLOAD BROCHURE

 

INTERESTED IN SPONSORING OR EXHIBITING?

Contact Andre Singer at andre.singer@terrapinn.com
or  +1 646 619 1797